Dietary bile acid supplementation improves intestinal integrity and survival in a murine model.
OBJECTIVE
In vitro supplementation of the bile salt, taurodeoxycholic acid (TDCA), has been shown to stimulate proliferation and prevent intestinal apoptosis in IEC-6 cells. We hypothesize that addition of TDCA to a rodent liquid diet will be protective against induced intestinal injury.


METHODS
C57Bl6 mice were fed a liquid diet with or without 50-mg/(kg d) TDCA supplementation. After 6 days, the mice were injected with lipopolysaccharide (LPS) (10 mg/kg) to induce intestinal injury. Specimens were obtained 24 hours later and evaluated for intestinal apoptosis, crypt proliferation, and villus length. A separate cohort of animals was injected with LPS (25 mg/kg) and followed 7 days for survival.


RESULTS
Mice whose diet was supplemented with TDCA had significantly increased survival. After LPS-induced injury, mice supplemented with TDCA showed decreased intestinal apoptosis by both H&E and caspase-3. They also had increased intestinal proliferation by 5-bromo-2'deoxyuridine staining and increased villus length.


CONCLUSIONS
Dietary TDCA supplementation alleviates mucosal damage and improves survival after LPS-induced intestinal injury. Taurodeoxycholic acid is protective of the intestinal mucosa by increasing resistance to injury-induced apoptosis, stimulating enterocyte proliferation, and increasing villus length. Taurodeoxycholic acid supplementation also results in an increased survival benefit. Therefore, bile acid supplementation may potentially protect the intestine from injury or infection.
Perrone
Erin E
EE
Department of Pediatric Surgery, University of Maryland Medical Center, Baltimore, MD 21201, USA.
Chen
Chen
C
Longshore
Shannon W
SW
Okezie
Oneybuchi
O
Warner
Brad W
BW
Sun
Chen-Chih
CC
Alaish
Samuel M
SM
Strauch
Eric D
ED
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D002756:Cholagogues and Choleretics / Q000008:administration & dosage* / Q000627:therapeutic use; D019587:Dietary Supplements; D004195:Disease Models, Animal; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D012778:Short Bowel Syndrome / Q000178:diet therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate / Q000639:trends; D013657:Taurodeoxycholic Acid / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome
D002756:Cholagogues and Choleretics; D013657:Taurodeoxycholic Acid